NASDAQ:SXTP

60 Degrees Pharma Nears FDA Deadline in Thin Holiday Trading
····

60 Degrees Pharma Nears FDA Deadline in Thin Holiday Trading

60 Degrees Pharmaceuticals (SXTP) closed unchanged at $1.48 Tuesday as investors awaited an FDA decision deadline on its Australian Chestnut Extract NDIN. The stock rose 6.5% last week but remains thinly traded. First-quarter net product revenue fell to $162,000, with a net loss of $2.21 million. Eric Francois joined the board on May 13, according to a May 18 filing.
May 25, 2026

Stock Market Today

  • DroneShield: A Strategic ASX Growth Share Amid Rising Counter-Drone Demand
    May 29, 2026, 7:32 PM EDT. DroneShield Ltd (ASX: DRO) targets the growing security threat posed by drones. Its niche focus on anti-drone technology positions it in a market driven by increasing defence and government demand. The company combines hardware and artificial intelligence-enabled software to counter evolving drone tactics, aiming to build recurring software revenue alongside hardware sales. Recent financial updates reveal strong cash flow, a robust sales pipeline, and global operational presence. While the potential is significant, defence contracts remain unpredictable, requiring cautious investor evaluation. DroneShield's blend of technology and strategic resources suggests it could be a compelling ASX growth share for long-term investors watching the defense tech sector.